Summary
This 2017 study used functional genetic screening to identify the PI3K signalling pathway as a key mediator of resistance to FGFR inhibitors in urothelial cell carcinoma harbouring FGFR mutations. The findings suggest that simultaneous inhibition of FGFR and PI3K pathways may enhance therapeutic efficacy in this cancer subtype, as indicated by the title's framing of PI3K as a 'determinant of resistance'. The research contributes to understanding of targetable mechanisms underlying acquired or intrinsic resistance in FGFR-driven cancers.
UK applicability
This basic cancer cell biology research has potential relevance to UK clinical oncology and drug development pathways for urothelial cancer treatment, though clinical translation would require further validation in human studies and regulatory review.
Key measures
PI3K pathway activity and FGFR inhibitor sensitivity in FGFR-mutant urothelial cancer cell lines
Outcomes reported
The study identified the phosphoinositide 3-kinase (PI3K) pathway as a determinant of resistance to fibroblast growth factor receptor (FGFR) inhibitors in FGFR-mutant urothelial cell carcinoma through functional genetic screening.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.